JP7078641B2 - 自己免疫疾患の治療のためのｒｎａ - Google Patents

自己免疫疾患の治療のためのｒｎａ Download PDF

Info

Publication number
JP7078641B2
JP7078641B2 JP2019555957A JP2019555957A JP7078641B2 JP 7078641 B2 JP7078641 B2 JP 7078641B2 JP 2019555957 A JP2019555957 A JP 2019555957A JP 2019555957 A JP2019555957 A JP 2019555957A JP 7078641 B2 JP7078641 B2 JP 7078641B2
Authority
JP
Japan
Prior art keywords
cells
immunogenic
uridine
mrna
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019555957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516658A (ja
JP2020516658A5 (enExample
Inventor
ウグル サヒン，
ゼバスティアン クライター，
クリスティーナ クリエンケ，
ユッタ ペチェンカ，
レナ マレーン クランツ，
ムスタファ ディケン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Original Assignee
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, BioNTech SE filed Critical Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Publication of JP2020516658A publication Critical patent/JP2020516658A/ja
Publication of JP2020516658A5 publication Critical patent/JP2020516658A5/ja
Priority to JP2022082384A priority Critical patent/JP7444924B2/ja
Application granted granted Critical
Publication of JP7078641B2 publication Critical patent/JP7078641B2/ja
Priority to JP2024025246A priority patent/JP2024059794A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019555957A 2017-04-11 2018-04-10 自己免疫疾患の治療のためのｒｎａ Active JP7078641B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022082384A JP7444924B2 (ja) 2017-04-11 2022-05-19 自己免疫疾患の治療のためのｒｎａ
JP2024025246A JP2024059794A (ja) 2017-04-11 2024-02-22 自己免疫疾患の治療のためのｒｎａ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/058651 2017-04-11
PCT/EP2017/058651 WO2018188730A1 (en) 2017-04-11 2017-04-11 Rna for treatment of autoimmune diseases
PCT/EP2018/059188 WO2018189193A1 (en) 2017-04-11 2018-04-10 Rna for treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022082384A Division JP7444924B2 (ja) 2017-04-11 2022-05-19 自己免疫疾患の治療のためのｒｎａ

Publications (3)

Publication Number Publication Date
JP2020516658A JP2020516658A (ja) 2020-06-11
JP2020516658A5 JP2020516658A5 (enExample) 2021-09-09
JP7078641B2 true JP7078641B2 (ja) 2022-05-31

Family

ID=58632945

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019555957A Active JP7078641B2 (ja) 2017-04-11 2018-04-10 自己免疫疾患の治療のためのｒｎａ
JP2022082384A Active JP7444924B2 (ja) 2017-04-11 2022-05-19 自己免疫疾患の治療のためのｒｎａ
JP2024025246A Ceased JP2024059794A (ja) 2017-04-11 2024-02-22 自己免疫疾患の治療のためのｒｎａ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022082384A Active JP7444924B2 (ja) 2017-04-11 2022-05-19 自己免疫疾患の治療のためのｒｎａ
JP2024025246A Ceased JP2024059794A (ja) 2017-04-11 2024-02-22 自己免疫疾患の治療のためのｒｎａ

Country Status (23)

Country Link
US (2) US11701413B2 (enExample)
EP (2) EP3981424A1 (enExample)
JP (3) JP7078641B2 (enExample)
KR (2) KR20240042138A (enExample)
CN (2) CN118161602A (enExample)
AU (1) AU2018253352B2 (enExample)
BR (1) BR112019020667A8 (enExample)
CA (1) CA3059505A1 (enExample)
CY (1) CY1124767T1 (enExample)
DK (1) DK3609529T3 (enExample)
ES (1) ES2893451T3 (enExample)
HR (1) HRP20211559T1 (enExample)
HU (1) HUE056871T2 (enExample)
IL (2) IL269793B (enExample)
LT (1) LT3609529T (enExample)
MX (1) MX2019012144A (enExample)
PL (1) PL3609529T3 (enExample)
PT (1) PT3609529T (enExample)
RS (1) RS62582B1 (enExample)
SG (2) SG10202111163VA (enExample)
SI (1) SI3609529T1 (enExample)
SM (1) SMT202100572T1 (enExample)
WO (2) WO2018188730A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024059794A (ja) * 2017-04-11 2024-05-01 バイオエヌテック エスエー 自己免疫疾患の治療のためのｒｎａ

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880174A2 (en) * 2018-11-12 2021-09-22 Translate Bio, Inc. Methods for inducing immune tolerance
CN118490818A (zh) * 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN115232825B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的新冠病毒疫苗
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
IL308571A (en) 2021-05-26 2024-01-01 Imcyse Sa Methods of treating or preventing autoimmune diseases
EP4355875A1 (en) * 2021-06-14 2024-04-24 2seventy bio, Inc. Single stranded rna purification methods
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
CN118369335A (zh) * 2022-01-06 2024-07-19 上海吉量医药工程有限公司 N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120626A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2017036889A1 (en) 2015-08-28 2017-03-09 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of rna

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
PL2578685T3 (pl) * 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
ES2769129T3 (es) 2009-12-07 2020-06-24 Univ Pennsylvania Preparaciones de ARN que comprenden ARN modificado purificado para reprogramar células
US9778250B2 (en) * 2011-05-10 2017-10-03 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
US20150044244A1 (en) * 2011-09-30 2015-02-12 Beijing Advanccine Biotechnology Co. Ltd. Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases
DK3421601T3 (da) * 2011-12-30 2020-02-24 Cellscript Llc Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
CN106395552B (zh) 2015-08-03 2020-03-17 奥的斯电梯公司 无绳电梯系统导轨组件
SI3445850T1 (sl) 2016-04-22 2021-12-31 BioNTech SE Postopki za zagotavljanje enoverižne RNA
WO2018188730A1 (en) * 2017-04-11 2018-10-18 Biontech Rna Pharmaceuticals Gmbh Rna for treatment of autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120626A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
WO2017036889A1 (en) 2015-08-28 2017-03-09 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of rna

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Immunity, 2005, Vol.23, pp.165-175
Molecular Therapy, 2008, Vol.16, No.11, pp.1833-1840
Molecular Therapy, 2012, Vol.20, No.5, pp.948-953

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024059794A (ja) * 2017-04-11 2024-05-01 バイオエヌテック エスエー 自己免疫疾患の治療のためのｒｎａ

Also Published As

Publication number Publication date
HUE056871T2 (hu) 2022-04-28
JP2020516658A (ja) 2020-06-11
ES2893451T3 (es) 2022-02-09
LT3609529T (lt) 2021-10-25
IL269793A (en) 2019-11-28
JP7444924B2 (ja) 2024-03-06
US20230330198A1 (en) 2023-10-19
US11701413B2 (en) 2023-07-18
KR102824942B1 (ko) 2025-06-25
RU2019135808A3 (enExample) 2021-08-10
CY1124767T1 (el) 2022-11-25
RS62582B1 (sr) 2021-12-31
WO2018188730A1 (en) 2018-10-18
KR20240042138A (ko) 2024-04-01
AU2018253352A1 (en) 2019-10-17
SG10202111163VA (en) 2021-11-29
EP3609529B1 (en) 2021-09-08
SMT202100572T1 (it) 2021-11-12
EP3981424A1 (en) 2022-04-13
CN118161602A (zh) 2024-06-11
RU2019135808A (ru) 2021-05-11
IL290980A (en) 2022-05-01
JP2022110127A (ja) 2022-07-28
PL3609529T3 (pl) 2021-12-13
SI3609529T1 (sl) 2021-11-30
JP2024059794A (ja) 2024-05-01
BR112019020667A8 (pt) 2022-08-16
EP3609529A1 (en) 2020-02-19
IL269793B (en) 2022-04-01
PT3609529T (pt) 2021-10-14
US20200061166A1 (en) 2020-02-27
CA3059505A1 (en) 2018-10-18
CN110719787B (zh) 2024-03-15
BR112019020667A2 (pt) 2020-05-05
MX2019012144A (es) 2019-11-21
HRP20211559T1 (hr) 2022-01-21
AU2018253352B2 (en) 2025-04-10
CN110719787A (zh) 2020-01-21
WO2018189193A1 (en) 2018-10-18
SG11201909520VA (en) 2019-11-28
KR20190134765A (ko) 2019-12-04
DK3609529T3 (da) 2021-10-11

Similar Documents

Publication Publication Date Title
JP7444924B2 (ja) 自己免疫疾患の治療のためのｒｎａ
JP2024105596A (ja) ネオ抗原およびその使用方法
JP2022515194A (ja) Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用
US12168051B2 (en) Methods and compositions for stimulating immune response
TW202245808A (zh) 用於治療癌症之治療性ｒｎａ
US20250277223A1 (en) Methods of treating or preventing autoimmune diseases
HK40070905A (en) Rna for treatment of autoimmune diseases
RU2790447C2 (ru) Рнк для лечения аутоиммунных заболеваний
HK40017292B (en) Rna for treatment of autoimmune diseases
HK40017292A (en) Rna for treatment of autoimmune diseases
HK40099663A (en) Therapeutic rna for treating cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210728

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7078641

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250